Godrej Agrovet Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹2,333Cr
- +9.3% YoY
- −14.2% QoQ
- Net profit
- ₹102Cr
- +54.5% YoY
- −7.3% QoQ
- Margin
- 6%
- −1 pp YoY
- −3 pp QoQ
Guidance rank: #24 of 33 in Food Products
See the sector's top 10 — free with your mobile number.
The short version
Astec LifeSciences: Targeting around 15%-20% top-line growth, with CDMO segment expected to grow slightly higher than the enterprise segment; margins to remain intact. Godrej Agrovet aims for early double-digit revenue growth at the consolidated level for FY27.
From Godrej Agrovet Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Astec LifeSciences: Targeting around 15%-20% top-line growth, with CDMO segment expected to grow slightly higher than the enterprise segment; margins to remain intact. CDMO revenue share aimed at 52%-53%+.
- Animal Nutrition: Strong volume growth continuing, particularly in cattle feed and newly launched products; focusing on volume-driven revenue growth with double-digit growth expected.
- Oil Palm: Early double-digit volume growth expected, with record area expansion planned; improving oil extraction ratio supports margins.
- Crop Care: Expected strong recovery from Q2 FY27 onwards, aiming for very high double-digit revenue growth post inventory normalization.
2 more points from Godrej Agrovet Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Godrej Agrovet Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Godrej Agrovet plans capex of around INR 350-400 crores per year going forward.
- Approximately 75%-80% of capex will be growth-oriented.
- Around 50% of total capex deployment is targeted toward the Oil Palm business.
- Specific investments include rolling out a specialty fat refinery starting May FY '27, expected to ramp up in the second half of the year.
- Investment focus on value-added products in Oil Palm to move the portfolio towards 50%-55% value-added products by FY31.
- Ongoing strategic restructuring and portfolio reviews to unlock shareholder value over a 4-5 year horizon.
2 more points from Godrej Agrovet Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Food Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Godrej Agrovet Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Godrej Agrovet Ltd's call on order book
Create a free account to keep reading this call
Godrej Agrovet Ltd — Quarterly revenue & net profit
Godrej Agrovet Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 2,333 | 2,134 | +9.3% | 2,718 | -14.2% |
| Operating profit (EBITDA) | 139 | 147 | -5.4% | 242 | -42.6% |
| Operating margin | 6% | 7% | -1 pp | 9% | -3 pp |
| Profit before tax | 130 | 87 | +49.4% | 146 | -11% |
| Net profit (PAT) | 102 | 66 | +54.5% | 110 | -7.3% |
| EPS (₹) | 5.45 | 3.68 | +48.1% | 5.97 | -8.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹3.0K Cr, net profit ₹103 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Godrej Agrovet's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
Earlier calls (2)
Others in Food Products this season
- HMA Agro Industries (Q4 FY26)
The company remains confident about sustaining a 25%-30% growth rate in revenue, supported by increased utilization and higher value-added product contribution…
- Coastal Corporat (Q4 FY26)
Total Income from Operations: ₹728.75 Cr . Key investor presentation takeaways from Coastal Corporat's Q4 FY26 investor presentation — and how it ranks against
- Megastar Foods (Q4 FY26)
Q4FY26 Revenue from Operations: ₹14,606 lakhs (Page 7) . Key investor presentation takeaways from Megastar Foods's Q4 FY26 investor presentation — and how it ra
- Mukka Proteins (Q4 FY26)
Q4 FY26 Revenue from Operations:** ₹381.6 Cr . Key concall takeaways from Mukka Proteins Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Food Products
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Godrej Agrovet Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Godrej Agrovet Ltd Q4 FY26 results?
Astec LifeSciences: Targeting around 15%-20% top-line growth, with CDMO segment expected to grow slightly higher than the enterprise segment; margins to remain intact. Godrej Agrovet aims for early double-digit revenue growth at the consolidated level for FY27.
What is Godrej Agrovet Ltd share price analysis?
Godrej Agrovet Ltd currently shows a neutral. The stock trades at a P/E of 23.8 with a market cap of ₹11,166 Cr. Investors should review the full earnings analysis for detailed insights.
Is Godrej Agrovet Ltd planning capital expenditure?
Godrej Agrovet plans capex of around INR 350-400 crores per year going forward.
Keep Godrej Agrovet Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
